Protocol Ledger

NCT04979442 · Phase III · TERMINATED

Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

Interventional Phase III clinical trial protocol NCT04979442 sponsored by Rain Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-14 Enrollment: 175 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04979442
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)175 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04979442
Protocol FieldVerified Registry Value
NCT IdentifierNCT04979442
Consolidated Lead SponsorRain Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment175 participants (ACTUAL)
Registered Start Date2021-07-14
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI